Core Viewpoint - Gilead Sciences (GILD.US) reported a nearly 9% increase in stock price, reaching $120.07, following better-than-expected financial results for Q2 2025, driven by key products [1] Financial Performance - Gilead Sciences' revenue for Q2 2025 grew by 2% to $7.08 billion, surpassing market expectations of $6.98 billion [1] - Adjusted earnings per share (EPS) were reported at $2.01, exceeding the market forecast of $1.96 [1] Future Guidance - For the full year, Gilead expects product sales to range between $28.3 billion and $28.7 billion, with an upward adjustment of $100 million on both ends [1] - The company anticipates EPS to be between $5.85 and $6.15, an increase from the previous range of $5.65 to $6.05 [1] - On an adjusted basis, Gilead forecasts EPS between $7.95 and $8.25, up from the earlier estimate of $7.70 to $8.10 [1] Key Growth Drivers - The growth in revenue is attributed to the performance of products such as Biktarvy, Descovy, Trodelvy, and Livdelzi [1]

Core Insights - Gilead Sciences is focusing on executing its strategy across core franchises, particularly in HIV and oncology, while also diversifying into inflammation [2][3] - The company has developed a strategy over the past 5 to 6 years to maintain leadership in virology and expand into other therapeutic areas [3] - Gilead currently has three growing franchises: virology and HIV, oncology, and inflammation, with promising data from recent presentations at ASCO [4] Financial Position - Gilead has a strong balance sheet and robust cash flows, positioning the company well for future growth opportunities [4]

Core Insights - GSK's new drug application for linerixibat has been accepted by the FDA for review, with a decision expected on March 24, 2026 [1][7] - If approved, linerixibat could fulfill a significant unmet medical need for patients suffering from cholestatic pruritus associated with primary biliary cholangitis (PBC) [2][5] GSK's Drug Development - The NDA for linerixibat is based on positive results from the phase III GLISTEN study, which demonstrated significant improvement in cholestatic pruritus and related sleep interference compared to placebo [4][7] - Cholestatic pruritus is a common symptom of PBC, a rare autoimmune disease that can lead to liver failure [5] Competitive Landscape - Other companies are also pursuing treatments for PBC, including Gilead Sciences, which received accelerated approval for seladelpar in August 2024 [8] - Seladelpar was acquired by Gilead for $4.3 billion and is now part of their liver disease portfolio [9] - Mirum Pharmaceuticals is developing volixibat, another oral IBAT inhibitor, currently in phase IIb trials [9]

Q125 Financial Results 10 December 2024 April 24, 2025 Forward-Looking Statements Statements included in this press release that are not historical in nature are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Gilead cautions readers that forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include those relating to: Gilead's ability to achieve its f ...